DE60026152D1 - Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs - Google Patents
Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebsInfo
- Publication number
- DE60026152D1 DE60026152D1 DE60026152T DE60026152T DE60026152D1 DE 60026152 D1 DE60026152 D1 DE 60026152D1 DE 60026152 T DE60026152 T DE 60026152T DE 60026152 T DE60026152 T DE 60026152T DE 60026152 D1 DE60026152 D1 DE 60026152D1
- Authority
- DE
- Germany
- Prior art keywords
- cancer
- acid
- medicament
- prevention
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US393790 | 1999-09-10 | ||
US09/393,790 US6340705B1 (en) | 1999-09-10 | 1999-09-10 | Use of α-linolenic acid metabolites for treatment or prevention of cancer |
PCT/US2000/024931 WO2001017517A2 (en) | 1999-09-10 | 2000-09-11 | Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60026152D1 true DE60026152D1 (de) | 2006-04-27 |
DE60026152T2 DE60026152T2 (de) | 2006-11-16 |
Family
ID=23556262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60026152T Expired - Lifetime DE60026152T2 (de) | 1999-09-10 | 2000-09-11 | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs |
Country Status (9)
Country | Link |
---|---|
US (2) | US6340705B1 (de) |
EP (1) | EP1237545B1 (de) |
JP (1) | JP2003508484A (de) |
AT (1) | ATE318133T1 (de) |
AU (1) | AU7371600A (de) |
CA (1) | CA2384502C (de) |
DE (1) | DE60026152T2 (de) |
MX (1) | MXPA02002681A (de) |
WO (1) | WO2001017517A2 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040037892A1 (en) * | 2001-11-19 | 2004-02-26 | Adrianne Bendich | Dietary composition containing conjugated linoleic acid and calcium for improved health |
WO2002092779A2 (en) * | 2001-05-17 | 2002-11-21 | Pilot Therapeutics, Inc. | Method for enriching tissues in long chain polyunsaturated fatty acids |
US6977271B1 (en) * | 2001-08-30 | 2005-12-20 | Health Research, Inc. | Method for inhibition of angiogenesis and vasculogenesis |
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
CA2436650A1 (en) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses |
EP1660071A1 (de) * | 2003-08-18 | 2006-05-31 | Btg International Limited | Behandlung von neurodegenerativen erkrankungen |
CN102134231B (zh) * | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
US7456270B2 (en) | 2004-09-01 | 2008-11-25 | Abbott Laboratories | Δ6-desaturase genes and uses thereof |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
US7481870B2 (en) * | 2006-04-18 | 2009-01-27 | Oreck Holdings, Llc | Electrode wire for an electrostatic precipitator |
HUE025064T2 (en) | 2006-06-08 | 2016-01-28 | Iams Europe B V | Use of at least one polyphenol to promote eye health |
FR2904554B1 (fr) * | 2006-08-04 | 2010-11-05 | Zheng Xu | Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
WO2009058799A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
BRPI0821395A2 (pt) * | 2007-12-19 | 2015-06-16 | Prometic Biosciences Inc | Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático |
US20090197955A1 (en) * | 2008-01-31 | 2009-08-06 | Monsanto Company | Methods of improving dha deposition and related function and/or development |
US8060617B2 (en) * | 2008-12-19 | 2011-11-15 | Cisco Technology, Inc. | Reserving network resources during scheduling of meeting event |
US8372465B2 (en) | 2010-02-17 | 2013-02-12 | Bunge Oils, Inc. | Oil compositions of stearidonic acid |
EP2425833A1 (de) * | 2010-09-03 | 2012-03-07 | Fresenius Kabi Deutschland GmbH | Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie |
WO2012141575A1 (en) * | 2011-04-14 | 2012-10-18 | N.V.Nutricia | Combination of epa, dpa and/or dha with a chemotherapeutic agent |
US10076550B2 (en) * | 2014-06-25 | 2018-09-18 | Council Of Scientific & Industrial Research | Synergistic pharmaceutical composition for gastroinestinal disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8302708D0 (en) | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
HU203660B (en) * | 1987-04-23 | 1991-09-30 | Biogal Gyogyszergyar | Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids |
CN1035925C (zh) * | 1988-11-16 | 1997-09-24 | 许正 | 亲细胞非均质分子脂质的制备方法 |
DE69004081T2 (de) * | 1990-05-23 | 1994-02-10 | Nestle Sa | Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen. |
GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
EP0585058A1 (de) * | 1992-08-25 | 1994-03-02 | Scotia Holdings Plc | Pharmazeutische Zusammensetzungen enthaltend Fettsäuren und Heparin |
EP0585057A1 (de) * | 1992-08-25 | 1994-03-02 | Scotia Holdings Plc | Lithiumsalzen von Fettsäuren zur Behandlung der viralen Infektionen und Krebs |
CA2119000A1 (en) | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
US5925669A (en) * | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
JPH0853351A (ja) * | 1994-08-11 | 1996-02-27 | Sagami Chem Res Center | 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤 |
KR970002037B1 (ko) * | 1994-12-09 | 1997-02-21 | 농촌진흥청 | 들깨유로부터 α-리놀렌산(ALA)을 분리, 정제하는 방법 |
US5639787A (en) * | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
ATE221324T1 (de) | 1996-11-20 | 2002-08-15 | Nutricia Nv | Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms |
DE19757414A1 (de) * | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
-
1999
- 1999-09-10 US US09/393,790 patent/US6340705B1/en not_active Expired - Lifetime
-
2000
- 2000-09-11 AT AT00961816T patent/ATE318133T1/de not_active IP Right Cessation
- 2000-09-11 MX MXPA02002681A patent/MXPA02002681A/es active IP Right Grant
- 2000-09-11 EP EP00961816A patent/EP1237545B1/de not_active Expired - Lifetime
- 2000-09-11 JP JP2001521308A patent/JP2003508484A/ja active Pending
- 2000-09-11 WO PCT/US2000/024931 patent/WO2001017517A2/en active IP Right Grant
- 2000-09-11 CA CA2384502A patent/CA2384502C/en not_active Expired - Fee Related
- 2000-09-11 AU AU73716/00A patent/AU7371600A/en not_active Abandoned
- 2000-09-11 DE DE60026152T patent/DE60026152T2/de not_active Expired - Lifetime
-
2001
- 2001-07-13 US US09/903,707 patent/US20020010211A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2384502C (en) | 2011-01-18 |
CA2384502A1 (en) | 2001-03-15 |
JP2003508484A (ja) | 2003-03-04 |
EP1237545B1 (de) | 2006-02-22 |
MXPA02002681A (es) | 2003-10-14 |
US6340705B1 (en) | 2002-01-22 |
DE60026152T2 (de) | 2006-11-16 |
WO2001017517A2 (en) | 2001-03-15 |
WO2001017517A3 (en) | 2002-07-11 |
AU7371600A (en) | 2001-04-10 |
EP1237545A2 (de) | 2002-09-11 |
US20020010211A1 (en) | 2002-01-24 |
ATE318133T1 (de) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60026152D1 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
ATE322902T1 (de) | Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten | |
ATE457187T1 (de) | Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie | |
DE60129550D1 (de) | Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten | |
DE69232485D1 (de) | VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten. | |
ATE191143T1 (de) | Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck | |
ATE406371T1 (de) | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
ATE274916T1 (de) | Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome | |
DE60203847D1 (de) | Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen | |
DE69916632D1 (de) | Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind | |
DE69829202D1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
DE69921662D1 (de) | Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose | |
DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
DE60229240D1 (de) | Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes | |
DE60027127D1 (de) | Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen | |
DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
ATE286402T1 (de) | Verwendung von morinda citrifolia zur behandlung von tinnitus | |
DE60206280D1 (de) | Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia | |
DE602004014974D1 (de) | Verwendung von zusammensetzungen mit oleansäure und ursolsäure zur herstellung eines medikaments zur behandlung von überempfindlichkeit und hyperreaktivität | |
ATE271881T1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen | |
ATE249832T1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |